Video Experimental Relacionado
Updated: Jan 13, 2026
07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.8K
IGF2BP2 impulsa la desdiferenciación del cáncer de tiroides a través de la desestabilización del ARNm de STAT1
Rui Chen1, Yi-Xun Li1, Wei-Lin Lu1
1Department of Breast Surgery, the First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, 210029, Nanjing, People's Republic of China.
International journal of biological sciences
|January 12, 2026
Resumen
IGF2BP2 impulsa la desdiferenciación del cáncer de tiroides al dirigirse al ARNm de STAT1, lo que conduce a un carcinoma tiroideo anaplásico (ATC) agresivo. Este descubrimiento ofrece un nuevo objetivo terapéutico para la terapia de rediferenciación en el cáncer de tiroides avanzado.
Área de la Ciencia:
- Endocrinología
- Oncología
- Biología Molecular
Sus antecedentes:
- El cáncer de tiroides es una neoplasia endocrina común.
- El carcinoma tiroideo anaplásico (ATC) es un subtipo agresivo y letal que surge de la desdiferenciación del carcinoma papilar de tiroides (PTC).
- Los mecanismos moleculares que impulsan la desdiferenciación del PTC a ATC siguen siendo en gran medida desconocidos.
Objetivo del estudio:
- Identificar los impulsores moleculares de la desdiferenciación del cáncer de tiroides.
- Elucidar el mecanismo por el cual estos impulsores promueven fenotipos tumorales agresivos.
- Establecer un objetivo terapéutico potencial para el cáncer de tiroides avanzado.
Principales métodos:
- Análisis de trayectoria de pseudotiempo de la expresión génica.
- Ensayos funcionales que evalúan la proliferación celular, la diferenciación y la estirpe de células cancerosas.
- Análisis integrado multiómico que incluye RNA-seq, RIP-seq y MeRIP-seq.
- Experimentos de rescate para validar los hallazgos mecanísticos.
Principales resultados:
- IGF2BP2 se sobreexpresa en el ATC y se correlaciona con un mal pronóstico.
- IGF2BP2 promueve la proliferación, mejora la estirpe de células cancerosas y suprime los genes de diferenciación tiroidea.
- IGF2BP2 se une al ARNm de STAT1 modificado por m6A, promoviendo su degradación.
- STAT1 es esencial para la desdiferenciación del cáncer de tiroides mediada por IGF2BP2.
Conclusiones:
- El complejo IGF2BP2-m6A-STAT1 es un regulador clave de la desdiferenciación del cáncer de tiroides.
- La focalización de este complejo representa una estrategia terapéutica novedosa para la terapia de rediferenciación en el cáncer de tiroides avanzado.
Videos de Conceptos Relacionados
01:16TGF - β Signaling Pathway
10.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.4K
02:23Master Transcription Regulators
7.7K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.7K
02:23Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
02:38Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
01:22PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K